Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke

Summary

To evaluate the safety and tolerability of IxCellhUC-MSC-S as a single intravenous infusion in convalescent patients with ischemic stroke. To explore the efficacy of IxCellhUC-MSC-S as a single intravenous infusion in patients with convalescent ischemic stroke.

Timeline

Start

2023-04-10

Primary completion

2024-07-29

Completion

2024-08-27

Publications

• Cui L, Xiao M, Zhang Q, Liu H, Ren Y, Ma G, Zhou D, Ma Q, Yao H, Lin M, Gao D, Ye L, Wang R, Wang Y, Zhang L, Zhong L, Gao G, Chen J, Jolkkonen J, Boltze J, Hao J. Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial. Cell Rep Med. 2026 Jun 16;7(6):102836. doi: 10.1016/j.xcrm.2026.102836. Epub 2026 May 28.

Drugs

Indications